In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance/Astellas: Quality Deal but without the Brand Name

Executive Summary

Branding works--in packaged goods and among investors. That's why, rather than taking Theravance's rich marketing deal with the Japanese company Astellas for the antibiotic telavancin -- rich in comparison to the best licensing deals signed in the segment -- as a net positive for the company, shareholders seemed disappointed.
Advertisement

Related Content

FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Theravance: Having Cake and Eating It
Theravance: Having Cake and Eating It
Yamanouchi/Fujisawa Merger: Closing Japanese Options
Millennium's P&L-Based Strategy and the Ortho/J&J Deal
Theravance Advances Respiratory Program via Glaxo Partnership

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel